This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT01414608) in the Standard Chemoradiation ARM group. Side effects include: Fatigue with 79%, Nausea with 76%, Diarrhea with 73%, Lymphocyte count decreased with 71%, Anemia with 65%.
2 Treatment Groups
Brachytherapy - Participants with > 35% biopsy core
1 of 2
Brachytherapy - Participants with < 35% biopsy core
1 of 2
300 Total Participants · 2 Treatment Groups
Primary Treatment: Brachytherapy · No Placebo Group · Phase 2
Brachytherapy - Participants with > 35% biopsy coreExperimental Group · 2 Interventions: Brachytherapy, Questionnaire · Intervention Types: Drug, Behavioral
Brachytherapy - Participants with < 35% biopsy coreExperimental Group · 2 Interventions: Brachytherapy, Questionnaire · Intervention Types: Drug, Behavioral
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Completed Phase 2
Screening: ~3 weeks
Reporting: 2.5 years
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,779 Previous Clinical Trials
1,784,463 Total Patients Enrolled
89 Trials studying Prostate Cancer
27,235 Patients Enrolled for Prostate Cancer
Steven J. Frank, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
442 Total Patients Enrolled
Age 18+ · Male Participants · 9 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a patient greater than or equal to 18 years of age.
You have a PSA level of less than or equal to 15 ng/ml.
Prostate volumes by TRUS less than or equal to 60 cc.
You have a bladder symptom score of 15 or greater.
You must sign a study-specific informed consent form prior to study entry.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.